Clinical Trial

A Dose-exploration Study of EDP167 in HoFH

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-03-27
Trial Details
NCT Number NCT07489209
Lead Sponsor Eddingpharm (Zhuhai) Co., Ltd.
Conditions Homozygous Familial Hypercholesterolemia (HoFH)
Enrollment 20 participants
Start Date 2026-02-06
Primary Completion 2026-10-04 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-20